
Global Drugs Based on Gene Therapy Market Analysis and Forecast 2025-2031
Description
Summary
According to APO Research, The global Drugs Based on Gene Therapy market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Drugs Based on Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Drugs Based on Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Drugs Based on Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Drugs Based on Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Drugs Based on Gene Therapy include Akcea Therapeutics, Alnylam Pharmaceuticals, AnGes, Biogen, Bluebird bio, Gilead Sciences, Human Stem Cells Institute, Orchard Therapeutics and Sarepta Therapeutics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Drugs Based on Gene Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Drugs Based on Gene Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Drugs Based on Gene Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Drugs Based on Gene Therapy revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Drugs Based on Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Drugs Based on Gene Therapy revenue, projected growth trends, production technology, application and end-user industry.
Drugs Based on Gene Therapy Segment by Company
Akcea Therapeutics
Alnylam Pharmaceuticals
AnGes
Biogen
Bluebird bio
Gilead Sciences
Human Stem Cells Institute
Orchard Therapeutics
Sarepta Therapeutics
SIBIONO
Spark Therapeutics
Sunway Biotech
Amgen
Novartis
Drugs Based on Gene Therapy Segment by Type
Viral Gene Therapy
Non-viral Gene Therapy
Drugs Based on Gene Therapy Segment by Application
Neurological Diseases
Cancer
Other
Drugs Based on Gene Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs Based on Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs Based on Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs Based on Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Drugs Based on Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Drugs Based on Gene Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs Based on Gene Therapy revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
According to APO Research, The global Drugs Based on Gene Therapy market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Drugs Based on Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Drugs Based on Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Drugs Based on Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Drugs Based on Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Drugs Based on Gene Therapy include Akcea Therapeutics, Alnylam Pharmaceuticals, AnGes, Biogen, Bluebird bio, Gilead Sciences, Human Stem Cells Institute, Orchard Therapeutics and Sarepta Therapeutics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Drugs Based on Gene Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Drugs Based on Gene Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Drugs Based on Gene Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Drugs Based on Gene Therapy revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Drugs Based on Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Drugs Based on Gene Therapy revenue, projected growth trends, production technology, application and end-user industry.
Drugs Based on Gene Therapy Segment by Company
Akcea Therapeutics
Alnylam Pharmaceuticals
AnGes
Biogen
Bluebird bio
Gilead Sciences
Human Stem Cells Institute
Orchard Therapeutics
Sarepta Therapeutics
SIBIONO
Spark Therapeutics
Sunway Biotech
Amgen
Novartis
Drugs Based on Gene Therapy Segment by Type
Viral Gene Therapy
Non-viral Gene Therapy
Drugs Based on Gene Therapy Segment by Application
Neurological Diseases
Cancer
Other
Drugs Based on Gene Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs Based on Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs Based on Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs Based on Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Drugs Based on Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Drugs Based on Gene Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs Based on Gene Therapy revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
Table of Contents
196 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Drugs Based on Gene Therapy Market by Type
- 1.2.1 Global Drugs Based on Gene Therapy Market Size by Type, 2020 VS 2024 VS 2031
- 1.2.2 Viral Gene Therapy
- 1.2.3 Non-viral Gene Therapy
- 1.3 Drugs Based on Gene Therapy Market by Application
- 1.3.1 Global Drugs Based on Gene Therapy Market Size by Application, 2020 VS 2024 VS 2031
- 1.3.2 Neurological Diseases
- 1.3.3 Cancer
- 1.3.4 Other
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Drugs Based on Gene Therapy Market Dynamics
- 2.1 Drugs Based on Gene Therapy Industry Trends
- 2.2 Drugs Based on Gene Therapy Industry Drivers
- 2.3 Drugs Based on Gene Therapy Industry Opportunities and Challenges
- 2.4 Drugs Based on Gene Therapy Industry Restraints
- 3 Global Growth Perspective
- 3.1 Global Drugs Based on Gene Therapy Market Perspective (2020-2031)
- 3.2 Global Drugs Based on Gene Therapy Growth Trends by Region
- 3.2.1 Global Drugs Based on Gene Therapy Market Size by Region: 2020 VS 2024 VS 2031
- 3.2.2 Global Drugs Based on Gene Therapy Market Size by Region (2020-2025)
- 3.2.3 Global Drugs Based on Gene Therapy Market Size by Region (2026-2031)
- 4 Competitive Landscape by Players
- 4.1 Global Drugs Based on Gene Therapy Revenue by Players
- 4.1.1 Global Drugs Based on Gene Therapy Revenue by Players (2020-2025)
- 4.1.2 Global Drugs Based on Gene Therapy Revenue Market Share by Players (2020-2025)
- 4.1.3 Global Drugs Based on Gene Therapy Players Revenue Share Top 10 and Top 5 in 2024
- 4.2 Global Drugs Based on Gene Therapy Key Players Ranking, 2023 VS 2024 VS 2025
- 4.3 Global Drugs Based on Gene Therapy Key Players Headquarters & Area Served
- 4.4 Global Drugs Based on Gene Therapy Players, Product Type & Application
- 4.5 Global Drugs Based on Gene Therapy Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Drugs Based on Gene Therapy Market CR5 and HHI
- 4.6.3 2024 Drugs Based on Gene Therapy Tier 1, Tier 2, and Tier 3
- 5 Drugs Based on Gene Therapy Market Size by Type
- 5.1 Global Drugs Based on Gene Therapy Revenue by Type (2020 VS 2024 VS 2031)
- 5.2 Global Drugs Based on Gene Therapy Revenue by Type (2020-2031)
- 5.3 Global Drugs Based on Gene Therapy Revenue Market Share by Type (2020-2031)
- 6 Drugs Based on Gene Therapy Market Size by Application
- 6.1 Global Drugs Based on Gene Therapy Revenue by Application (2020 VS 2024 VS 2031)
- 6.2 Global Drugs Based on Gene Therapy Revenue by Application (2020-2031)
- 6.3 Global Drugs Based on Gene Therapy Revenue Market Share by Application (2020-2031)
- 7 Company Profiles
- 7.1 Akcea Therapeutics
- 7.1.1 Akcea Therapeutics Comapny Information
- 7.1.2 Akcea Therapeutics Business Overview
- 7.1.3 Akcea Therapeutics Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
- 7.1.4 Akcea Therapeutics Drugs Based on Gene Therapy Product Portfolio
- 7.1.5 Akcea Therapeutics Recent Developments
- 7.2 Alnylam Pharmaceuticals
- 7.2.1 Alnylam Pharmaceuticals Comapny Information
- 7.2.2 Alnylam Pharmaceuticals Business Overview
- 7.2.3 Alnylam Pharmaceuticals Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
- 7.2.4 Alnylam Pharmaceuticals Drugs Based on Gene Therapy Product Portfolio
- 7.2.5 Alnylam Pharmaceuticals Recent Developments
- 7.3 AnGes
- 7.3.1 AnGes Comapny Information
- 7.3.2 AnGes Business Overview
- 7.3.3 AnGes Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
- 7.3.4 AnGes Drugs Based on Gene Therapy Product Portfolio
- 7.3.5 AnGes Recent Developments
- 7.4 Biogen
- 7.4.1 Biogen Comapny Information
- 7.4.2 Biogen Business Overview
- 7.4.3 Biogen Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
- 7.4.4 Biogen Drugs Based on Gene Therapy Product Portfolio
- 7.4.5 Biogen Recent Developments
- 7.5 Bluebird bio
- 7.5.1 Bluebird bio Comapny Information
- 7.5.2 Bluebird bio Business Overview
- 7.5.3 Bluebird bio Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
- 7.5.4 Bluebird bio Drugs Based on Gene Therapy Product Portfolio
- 7.5.5 Bluebird bio Recent Developments
- 7.6 Gilead Sciences
- 7.6.1 Gilead Sciences Comapny Information
- 7.6.2 Gilead Sciences Business Overview
- 7.6.3 Gilead Sciences Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
- 7.6.4 Gilead Sciences Drugs Based on Gene Therapy Product Portfolio
- 7.6.5 Gilead Sciences Recent Developments
- 7.7 Human Stem Cells Institute
- 7.7.1 Human Stem Cells Institute Comapny Information
- 7.7.2 Human Stem Cells Institute Business Overview
- 7.7.3 Human Stem Cells Institute Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
- 7.7.4 Human Stem Cells Institute Drugs Based on Gene Therapy Product Portfolio
- 7.7.5 Human Stem Cells Institute Recent Developments
- 7.8 Orchard Therapeutics
- 7.8.1 Orchard Therapeutics Comapny Information
- 7.8.2 Orchard Therapeutics Business Overview
- 7.8.3 Orchard Therapeutics Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
- 7.8.4 Orchard Therapeutics Drugs Based on Gene Therapy Product Portfolio
- 7.8.5 Orchard Therapeutics Recent Developments
- 7.9 Sarepta Therapeutics
- 7.9.1 Sarepta Therapeutics Comapny Information
- 7.9.2 Sarepta Therapeutics Business Overview
- 7.9.3 Sarepta Therapeutics Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
- 7.9.4 Sarepta Therapeutics Drugs Based on Gene Therapy Product Portfolio
- 7.9.5 Sarepta Therapeutics Recent Developments
- 7.10 SIBIONO
- 7.10.1 SIBIONO Comapny Information
- 7.10.2 SIBIONO Business Overview
- 7.10.3 SIBIONO Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
- 7.10.4 SIBIONO Drugs Based on Gene Therapy Product Portfolio
- 7.10.5 SIBIONO Recent Developments
- 7.11 Spark Therapeutics
- 7.11.1 Spark Therapeutics Comapny Information
- 7.11.2 Spark Therapeutics Business Overview
- 7.11.3 Spark Therapeutics Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
- 7.11.4 Spark Therapeutics Drugs Based on Gene Therapy Product Portfolio
- 7.11.5 Spark Therapeutics Recent Developments
- 7.12 Sunway Biotech
- 7.12.1 Sunway Biotech Comapny Information
- 7.12.2 Sunway Biotech Business Overview
- 7.12.3 Sunway Biotech Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
- 7.12.4 Sunway Biotech Drugs Based on Gene Therapy Product Portfolio
- 7.12.5 Sunway Biotech Recent Developments
- 7.13 Amgen
- 7.13.1 Amgen Comapny Information
- 7.13.2 Amgen Business Overview
- 7.13.3 Amgen Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
- 7.13.4 Amgen Drugs Based on Gene Therapy Product Portfolio
- 7.13.5 Amgen Recent Developments
- 7.14 Novartis
- 7.14.1 Novartis Comapny Information
- 7.14.2 Novartis Business Overview
- 7.14.3 Novartis Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
- 7.14.4 Novartis Drugs Based on Gene Therapy Product Portfolio
- 7.14.5 Novartis Recent Developments
- 8 North America
- 8.1 North America Drugs Based on Gene Therapy Revenue (2020-2031)
- 8.2 North America Drugs Based on Gene Therapy Revenue by Type (2020-2031)
- 8.2.1 North America Drugs Based on Gene Therapy Revenue by Type (2020-2025)
- 8.2.2 North America Drugs Based on Gene Therapy Revenue by Type (2026-2031)
- 8.3 North America Drugs Based on Gene Therapy Revenue Share by Type (2020-2031)
- 8.4 North America Drugs Based on Gene Therapy Revenue by Application (2020-2031)
- 8.4.1 North America Drugs Based on Gene Therapy Revenue by Application (2020-2025)
- 8.4.2 North America Drugs Based on Gene Therapy Revenue by Application (2026-2031)
- 8.5 North America Drugs Based on Gene Therapy Revenue Share by Application (2020-2031)
- 8.6 North America Drugs Based on Gene Therapy Revenue by Country
- 8.6.1 North America Drugs Based on Gene Therapy Revenue by Country (2020 VS 2024 VS 2031)
- 8.6.2 North America Drugs Based on Gene Therapy Revenue by Country (2020-2025)
- 8.6.3 North America Drugs Based on Gene Therapy Revenue by Country (2026-2031)
- 8.6.4 United States
- 8.6.5 Canada
- 9 Europe
- 9.1 Europe Drugs Based on Gene Therapy Revenue (2020-2031)
- 9.2 Europe Drugs Based on Gene Therapy Revenue by Type (2020-2031)
- 9.2.1 Europe Drugs Based on Gene Therapy Revenue by Type (2020-2025)
- 9.2.2 Europe Drugs Based on Gene Therapy Revenue by Type (2026-2031)
- 9.3 Europe Drugs Based on Gene Therapy Revenue Share by Type (2020-2031)
- 9.4 Europe Drugs Based on Gene Therapy Revenue by Application (2020-2031)
- 9.4.1 Europe Drugs Based on Gene Therapy Revenue by Application (2020-2025)
- 9.4.2 Europe Drugs Based on Gene Therapy Revenue by Application (2026-2031)
- 9.5 Europe Drugs Based on Gene Therapy Revenue Share by Application (2020-2031)
- 9.6 Europe Drugs Based on Gene Therapy Revenue by Country
- 9.6.1 Europe Drugs Based on Gene Therapy Revenue by Country (2020 VS 2024 VS 2031)
- 9.6.2 Europe Drugs Based on Gene Therapy Revenue by Country (2020-2025)
- 9.6.3 Europe Drugs Based on Gene Therapy Revenue by Country (2026-2031)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Netherlands
- 10 China
- 10.1 China Drugs Based on Gene Therapy Revenue (2020-2031)
- 10.2 China Drugs Based on Gene Therapy Revenue by Type (2020-2031)
- 10.2.1 China Drugs Based on Gene Therapy Revenue by Type (2020-2025)
- 10.2.2 China Drugs Based on Gene Therapy Revenue by Type (2026-2031)
- 10.3 China Drugs Based on Gene Therapy Revenue Share by Type (2020-2031)
- 10.4 China Drugs Based on Gene Therapy Revenue by Application (2020-2031)
- 10.4.1 China Drugs Based on Gene Therapy Revenue by Application (2020-2025)
- 10.4.2 China Drugs Based on Gene Therapy Revenue by Application (2026-2031)
- 10.5 China Drugs Based on Gene Therapy Revenue Share by Application (2020-2031)
- 11 Asia (Excluding China)
- 11.1 Asia Drugs Based on Gene Therapy Revenue (2020-2031)
- 11.2 Asia Drugs Based on Gene Therapy Revenue by Type (2020-2031)
- 11.2.1 Asia Drugs Based on Gene Therapy Revenue by Type (2020-2025)
- 11.2.2 Asia Drugs Based on Gene Therapy Revenue by Type (2026-2031)
- 11.3 Asia Drugs Based on Gene Therapy Revenue Share by Type (2020-2031)
- 11.4 Asia Drugs Based on Gene Therapy Revenue by Application (2020-2031)
- 11.4.1 Asia Drugs Based on Gene Therapy Revenue by Application (2020-2025)
- 11.4.2 Asia Drugs Based on Gene Therapy Revenue by Application (2026-2031)
- 11.5 Asia Drugs Based on Gene Therapy Revenue Share by Application (2020-2031)
- 11.6 Asia Drugs Based on Gene Therapy Revenue by Country
- 11.6.1 Asia Drugs Based on Gene Therapy Revenue by Country (2020 VS 2024 VS 2031)
- 11.6.2 Asia Drugs Based on Gene Therapy Revenue by Country (2020-2025)
- 11.6.3 Asia Drugs Based on Gene Therapy Revenue by Country (2026-2031)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
- 12 South America, Middle East and Africa
- 12.1 SAMEA Drugs Based on Gene Therapy Revenue (2020-2031)
- 12.2 SAMEA Drugs Based on Gene Therapy Revenue by Type (2020-2031)
- 12.2.1 SAMEA Drugs Based on Gene Therapy Revenue by Type (2020-2025)
- 12.2.2 SAMEA Drugs Based on Gene Therapy Revenue by Type (2026-2031)
- 12.3 SAMEA Drugs Based on Gene Therapy Revenue Share by Type (2020-2031)
- 12.4 SAMEA Drugs Based on Gene Therapy Revenue by Application (2020-2031)
- 12.4.1 SAMEA Drugs Based on Gene Therapy Revenue by Application (2020-2025)
- 12.4.2 SAMEA Drugs Based on Gene Therapy Revenue by Application (2026-2031)
- 12.5 SAMEA Drugs Based on Gene Therapy Revenue Share by Application (2020-2031)
- 12.6 SAMEA Drugs Based on Gene Therapy Revenue by Country
- 12.6.1 SAMEA Drugs Based on Gene Therapy Revenue by Country (2020 VS 2024 VS 2031)
- 12.6.2 SAMEA Drugs Based on Gene Therapy Revenue by Country (2020-2025)
- 12.6.3 SAMEA Drugs Based on Gene Therapy Revenue by Country (2026-2031)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
- 13 Concluding Insights
- 14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.